Summary The 2015 Magnetic Resonance Imaging in Multiple Sclerosis and 2016
Consortium of Multiple Sclerosis Centres guidelines on the use of MRI in diagnosis and …

Personalized treatment is ideal for multiple sclerosis (MS) owing to the heterogeneity of
clinical features, but current knowledge gaps, including validation of biomarkers and …

Early evaluation of treatment response and prediction of disease evolution are key issues in
the management of people with multiple sclerosis (MS). In the past 20 years, MRI has …

The Canadian Multiple Sclerosis Working Group has updated its treatment optimization
recommendations (TORs) on the optimal use of disease-modifying therapies for patients …

Despite that the availability of new therapeutic options has expanded the multiple sclerosis
(MS) disease-modifying therapy arsenal, interferon β (IFN-β) remains an important therapy …

Over the last few decades, the improved diagnostic criteria, the wide use of MRI, and the
growing availability of effective pharmacologic treatments have led to substantial advances …

The interaction between ageing and multiple sclerosis is complex and carries significant
implications for patient care. Managing multiple sclerosis effectively requires an …

1Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute
of Neurology, London, UK; 2National Hospital for Neurology and Neurosurgery, Queen …

While the major phenotypes of multiple sclerosis (MS) and relapsing–remitting, primary and
secondary progressive MS have been well characterized, a subgroup of patients with an …

Background and Objectives To estimate the proportions of patients with relapsing-remitting
multiple sclerosis who despite achieving the no evidence of disease activity-3 (NEDA-3) …